Who Paid My Doc
Patrick Gipson
Nephrology Washington, DC Medical Doctor
NPI 1144231531 CMS profile 566367
2150 Pennsylvania Ave Nw, Washington, DC 20037
General payments
$51
Research payments
$0
Ownership & investment interest
$0
Research they led as principal investigator
$342,906
Through program year 2022, Patrick Gipson of Washington, DC is reported in the CMS Open Payments database as having received $51 across 2 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $342,906 in research payments, paid to institutions rather than to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.
General payments for this record sit in the 8th percentile of Nephrology profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
2 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2022 | General | $12 | 1 | |
| 2019 | General | $39 | 1 |
Beside peers
- Patrick Gipson
- Nephrology median
- Middle half of Nephrology
- National median
In program year 2025, general payments to Patrick Gipson were reported at $0. Among 8,186 Nephrology profiles paid that year, the median was $310 and the middle half received between $104 and $880.
Show as a table
| Year | Patrick Gipson | Nephrology median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $39 | $236 | $90–$588 | $163 |
| 2020 | $0 | $135 | $46–$364 | $114 |
| 2021 | $0 | $202 | $67–$551 | $132 |
| 2022 | $12 | $242 | $77–$695 | $149 |
| 2023 | $0 | $254 | $84–$766 | $160 |
| 2024 | $0 | $300 | $99–$852 | $164 |
| 2025 | $0 | $310 | $104–$880 | $169 |
Breakdown
Prescribing to Medicare patients
Part D · data year 2024 · 4 drugsPart D claims
60
Drug cost
$40,235
Branded share of claims
76.7%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Jardiance Empagliflozin | Brand | 22 | $27,597 | |
| Farxiga Dapagliflozin Propanediol | Brand | 12 | $12,156 | |
| Valsartan | Generic | 14 | $275 | |
| Nifedipine Er Nifedipine | Brand | 12 | $207 |
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 9,003 Part D prescribers listed as Nephrology; they describe a distribution and say nothing about conduct.
Billing to Medicare
Part B · data year 2024 · 31 billing codesPaid by Medicare
$61,261
Medicare patients
198
Services billed
1,041
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| High blood pressure | 75% | |
| Chronic kidney disease | 75% | |
| Arthritis | 61% | |
| Diabetes | 60% | |
| Ischemic heart disease | 54% | |
| Heart failure | 49% | |
| COPD | 32% | |
| Depression | 30% |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Records
2 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Nephrology in District of Columbia
Related records
Nephrology in District of Columbia
Practitioners in the same specialty and state, ranked by reported value.
All Nephrology
Everyone recorded under this specialty, nationwide.
Doctors in District of Columbia
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.